Ionis Pharmaceuticals reports $243 million in third-quarter revenue
IONS Ionis Pharmaceuticals Inc
$31.00 -21.36%
View chart & analysis → - 1Excluding one-time payments from the previous year, Ionis Pharmaceuticals' total third-quarter revenue growth is 55%.
- 2Ionis Pharmaceuticals lowered its annual TRYNGOLZA net product sales target to approximately $50 million.
- 3Ionis Pharmaceuticals pushed back the expected timing of sustained positive cash flow by one year to 2029.
So what's the key point?
Ionis Pharmaceuticals' third-quarter revenue increased by 55% compared to last year. However, the sales target for a specific drug was lowered, and the timing for when cash flow becomes consistently positive was delayed to 2029.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.